XRP products gained ~$3.5m last week while crypto funds lost ~$288m. XRP (XRP)-linked investment products attracted approximately $3.5 million in net capital inflowsXRP products gained ~$3.5m last week while crypto funds lost ~$288m. XRP (XRP)-linked investment products attracted approximately $3.5 million in net capital inflows

XRP bucks trend with $3.5m inflows as crypto funds bleed

2026/02/24 19:39
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

XRP products gained ~$3.5m last week while crypto funds lost ~$288m.

Summary
  • Crypto investment products saw ~$288m in weekly outflows, extending a five-week streak that has pulled about $4b from digital asset funds amid the lowest trading volumes since mid‑2025.
  • BTC products lost ~$215m last week, taking YTD outflows to ~$1.3b, while ETH, TRX and multi‑asset products saw ~$36.5m, ~$18.9m and ~$32.5m exit respectively; short‑BTC vehicles drew ~$5.5m in fresh capital.
  • XRP drew ~$3.5m of inflows on the week and ~$33.4m the week before, lifting month‑to‑date and YTD inflows to about $105m and $151m; SOL added ~$3.3m and LINK ~$1.2m over the same period.

XRP (XRP)-linked investment products attracted approximately $3.5 million in net capital inflows last week, even as broader cryptocurrency products experienced outflows totaling $288 million, according to the latest CoinShares weekly flow report.

The data marks the fifth consecutive week of net withdrawals from crypto investment vehicles, pushing cumulative outflows to approximately $4 billion over this period, the report stated. Trading volumes have declined to their lowest levels since July 2025.

The United States represented the largest source of global outflows, with investors withdrawing $347 million in a single week, according to the report. In contrast, Switzerland recorded $19.5 million in inflows, Canada added $16.8 million, and Germany attracted $16.2 million, totaling approximately $59 million in combined inflows.

Bitcoin-linked investment products recorded $215 million in outflows during the week, pushing year-to-date withdrawals to around $1.3 billion, the data showed. Ethereum-related products experienced $36.5 million in weekly outflows, while Tron-related products recorded $18.9 million in outflows and multi-asset products saw $32.5 million exit. Short-Bitcoin products attracted $5.5 million in inflows, according to CoinShares.

XRP remained among the few cryptocurrencies to attract new capital during the market pullback, drawing $3.5 million in fresh inflows last week and $33.4 million the week prior, the report stated. The token’s month-to-date inflows reached $105 million, with year-to-date inflows totaling $151 million.

Solana-linked products recorded inflows of $3.3 million last week, bringing its month-to-date total to approximately $41.6 million and its year-to-date figure to about $102.5 million, according to the data. Chainlink products attracted $1.2 million in inflows.

The divergence in flows suggests investors are reallocating capital within the cryptocurrency sector rather than exiting entirely, according to market analysts. XRP trades at a lower price point than Bitcoin, potentially lowering barriers to entry for some investors. The token has also benefited from regulatory clarity following legal proceedings, analysts noted.

Total crypto trading volume fell to its lowest level since mid-2025, reflecting reduced market participation, the CoinShares report indicated.

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3666
$1.3666$1.3666
+0.74%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09